Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...

Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, demonstrating clinical ...

Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end. Encouraging clinical responses observed in ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

The first objective is to better identify the remaining unmet needs of patients and to direct R&D efforts where they ... industry in 1996 when he joined Merck, Sharp & Dohme (MSD) at the UK ...

On Friday, North Penn Vol. Fire Co. in North Wales Borough recognized 60 years since the death of one of their own in the ...

Under this partnership, Teijin and Hilleman Laboratories will leverage their individual strengths to foster greater synergy ...

Innovative drug development "the flavor of 2025" says Ali Pashazadeh, who discusses how the new administration will likely ...

He was a pioneer of new methods in the industry, being one of the first to focus on R&D as well as manufacturing ... whilst “American” Merck (now Merck & Co. in the US or Merck Sharp ...

Abbott Laboratories and Merck, Sharp and Dohme. His guidance will reinforce Morphocell’s strategic direction as the company continues its mission to transform patient outcomes through ...

Stanley B. PRUSINIER M.D., Nobel Laureate, Professor of Neurology, Director, Institute for Neurodegenerative Diseases, University of California, San Francisco Philipp A. SHARP Ph.D., Nobel Laureate, ...